Zimmer Biomet Holdings (ZBH) is in focus after second quarter results topped Wall Street expectations, with management pointing to hip market share gains, expanding technology and robotics adoption, and fresh products like the Z1 hip stem and OrthoGrid navigation.

The recent second quarter beat and ongoing buyback program have coincided with building momentum in Zimmer Biomet Holdings’ share price, with a 90 day share price return of 20.25% and year to date share price return of 11.81%, even though the 1 year total shareholder return is slightly down 1.01% and the 5 year total shareholder return is down 25.52%.

If Zimmer Biomet’s focus on robotics and digital tools has caught your attention, you may also want to see what is happening across other healthcare technology opportunities by checking the 44 healthcare AI stocks.

Zimmer Biomet Holdings’ share price has already reacted to the upbeat quarter and buybacks, yet analyst targets and intrinsic value estimates still point to a gap. So where does fair value really sit after this latest move?

Most Popular Narrative: 1.5% Undervalued

The most followed narrative for Zimmer Biomet Holdings pegs fair value at $102.19, only slightly above the last close of $100.65. That small gap puts the focus squarely on the earnings and margin story that underpins the model.

The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.

Want to see what sits behind that higher earnings and margin profile for Zimmer Biomet Holdings? The narrative leans on steady top line progress, fatter margins, and a future earnings multiple that differs from where similar medical equipment stocks sit today.

Result: Fair Value of $102.19 (UNDERVALUED)

However, you still need to weigh risks for Zimmer Biomet Holdings, including flat selling prices that could pressure margins and tougher competition in robotics from rivals such as Stryker.

Next Steps

If this mix of optimism and concern around Zimmer Biomet Holdings feels familiar, move fast and review the data for yourself. Start with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Zimmer Biomet?

If you are serious about building a stronger portfolio, do not stop at Zimmer Biomet Holdings. Use the Simply Wall Street Screener to quickly surface clear, data driven ideas that fit your style.

• Target reliable income streams by reviewing stocks in the 10 dividend fortresses and see which companies currently offer higher yields with supporting fundamentals.
• Spot potential value opportunities sooner by scanning the screener containing 18 high quality undiscovered gems and identify companies that the wider market may not be focusing on yet.
• Reduce portfolio stress by filtering for sturdier companies through the 83 resilient stocks with low risk scores and see which stocks align better with a lower risk profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.